<DOC>
	<DOCNO>NCT00922441</DOCNO>
	<brief_summary>The purpose study evaluate antihypertensive efficacy safety Fimasartan ( BR-A-657•K ) 24 hour dose patient mild moderate essential hypertension .</brief_summary>
	<brief_title>A Therapeutic Exploratory Clinical Study Evaluate Antihypertensive Efficacy Fimasartan ( BR-A-657•K ) During 24 Hours Patients With Mild Moderate Essential Hypertension</brief_title>
	<detailed_description>Fimasartan ( BR-A-657-K ) , selective blocker AT1 receptor subtype , show rapid potent antihypertensive effect many hypertensive model . Phase I study , Fimasartan ( BR-A-657-K ) 20mg ~ 480mg single dose healthy subject , demonstrate Fimasartan ( BR-A-657-K ) safe well tolerate . Another phase I study , Fimasartan ( BR-A-657-K ) 120mg 360mg dose 7 day , also show Fimasartan ( BR-A-657-K ) safe tolerable though one temporal adverse event observe high dose . A Randomized , Double-blind , Valsartan-referenced , Parallel Grouped , Therapeutic Exploratory Clinical Study Evaluate Antihypertensive Efficacy Fimasartan ( BR-A-657•K ) 24hoursby dose Patients Mild Moderate Essential Hypertension . Approximately 90 patient enrol 12 month 5 center nationwide . After 2 week placebo run-in period , subject randomize one follow 3 group . Subjects take test/control drug 8 week treatment period . If subject take antihypertensive medication screen , subject 1 week wash-out period . Group I : Fimasartan 60mg group . Group II : Fimasartan 120mg group Group III : Valsartan 80mg group</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Mild moderate essential hypertension : sit diastolic blood pressure measure Placebo visit Baseline 90~109mmHg inclusive difference sit diastolic blood pressure measure Placebo visit Baseline ( Day0 ) 7mmHg . Subjects agree participate sudy give write informed consent Subjects consider understand study , cooperative , able followedup end study The sit DBP le 89mmHg 110mmHg severe hypertensive patient sit systolic blood pressure 200mmHg Patients secondary hypertension Patients severe renal ( Creatinine 1.5mg/dl ) , gastrointestinal , hematological hepatic ( AST , ALT 2 twice upper limit normal ) disease etc . might affect absorption , disposition , metabolism excretion drug Patients postural hypotension Patients sever insulin dependent diabetes mellitus uncontrolled diabetes mellitus ( HbA1c &gt; 9 % , regimen change oral hypoglycemic agent within 12weeks , treat insulin screen ) Patients history myocardial infarction , severe coronary artery disease clinically significant heart failure valvular defect last 6 month Patients consumptive disease , autoimmune disease , connective tissue disease Patients history type B C hepatitis Patients HIV hepatitis Patients clinically significant laboratory abnormality Patients receive drug know affect blood pressure medical treatment influence blood pressure Patients allergy contraindication angiotensin II receptor antagonist Female childbearing potential undergo hysterectomy postmenopausal Patients judge history alcohol drug abuse investigator Patients participate clinical trial 12 week Screening Patients judge inappropriate study investigator reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Fimasartan</keyword>
	<keyword>Essential Hypertension</keyword>
	<keyword>24hour ABPM</keyword>
	<keyword>Population PK</keyword>
</DOC>